Skip to main content
Year archive

NEUROTECH INTERNATIONAL LIMITED — 2025 filings

All 46 regulatory filings released by NEUROTECH INTERNATIONAL LIMITED (NTI) in 2025, sourced directly from the official regulator.

46 Filings
2025 Period
2025 filings (46)
Filing Released Lang
Application for quotation of securities - NTI 6 pages 18.3KB
Share Issue/Capital Change
2025-12-23 English
Secondary Trading Notice 1 page 68.3KB
Share Issue/Capital Change
2025-12-23 English
Notification of cessation of securities - NTI 4 pages 14.8KB
Share Issue/Capital Change
2025-12-22 English
Change of Director's Interest Notice 2 pages 129.4KB
Director's Dealing
2025-12-22 English
Binding Commitments Received for a $4 Million Placement 2 pages 290.6KB
Capital/Financing Update
2025-12-16 English
Proposed issue of securities - NTI 5 pages 18.3KB
Capital/Financing Update
2025-12-16 English
Proposed issue of securities - NTI 5 pages 18.2KB
Capital/Financing Update
2025-12-16 English
Trading Halt 2 pages 200.8KB
Capital/Financing Update
2025-12-14 English
Presentation to 2025 Annual General Meeting 23 pages 1.7MB
AGM Information
2025-11-19 English
Results of Meeting 2 pages 224.2KB
Declaration of Voting Results & Voting Rights Announcements
2025-11-19 English
Neurotech receives $4.73m R&D Tax Incentive Refund 1
Regulatory Filings
2025-11-11 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 334.3KB
Interim / Quarterly Report
2025-10-27 English
Notice of Annual General Meeting/Proxy Form 22 pages 502.3KB
AGM Information
2025-10-19 English
Annual Report (Typeset) 31 pages 5.4MB
Annual Report
2025-10-15 English
US FDA Rare Pediatric Disease Designation in Rett syndrome 2 pages 255.1KB
Capital/Financing Update
2025-10-07 English
Neurotech initiates NTI164 Authorised Prescriber Program 2 pages 220.4KB
Regulatory Filings
2025-09-22 English
Release of Shares from Voluntary Escrow 1 page 86.1
Share Issue/Capital Change
2025-09-04 English
Appendix 4E & Annual Report to shareholders 63 pages 2.1MB
Annual Report
2025-08-28 English
Appendix 4G and Corporate Governance Statement 24 pages 685.4KB
Governance Information
2025-08-28 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 492.5KB
Interim / Quarterly Report
2025-07-30 English
Change of Registered Address & Principal Place of Business 1
Regulatory Filings
2025-07-09 English
Becoming a substantial holder 3 pages 208.5KB
Major Shareholding Notification
2025-07-08 English
New Scientific Publication of Phase I/II Rett Syndrome Trial 2 pages 272.9KB
Regulatory Filings
2025-07-06 English
NTI Appoints Dr. Bonni Goldstein as Chief Medical Advisor 2 pages 130.4KB
Board/Management Information
2025-06-15 English
NTI164 to be presented at IRSF Annual Scientific Meeting 2 pages 102.4KB
Regulatory Filings
2025-06-05 English
Positive Human PK Study Results for NTI164 3 pages 127.1KB
Regulatory Filings
2025-06-01 English
NTI164 Preclinical Toxicology Studies Update 2 pages 115.9KB
Regulatory Filings
2025-05-04 English
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 336.5KB
Interim / Quarterly Report
2025-04-27 English
Updated Trading Policy 6 pages 196.8KB
Regulatory Filings
2025-04-15 English
Final Director's Interest Notice 2 pages 154.2KB
Director's Dealing
2025-04-01 English
Application for quotation of securities - NTI 6 pages 18.5KB
Share Issue/Capital Change
2025-04-01 English
Secondary Trading Notice 1 page 88.4KB
Regulatory Filings
2025-04-01 English
Resignation of Executive Director 1 page 103.9KB
Board/Management Information
2025-03-31 English
European Commission grants NTI164 ODD for Rett Syndrome 2 pages 113.3KB
Regulatory Filings
2025-03-30 English
Retraction of Statement 1 page 71.1KB
Regulatory Filings
2025-03-25 English
New Scientific Publication of Phase I/II Autism Trial 2 pages 126.6KB
Regulatory Filings
2025-03-23 English
Neurotech Presentation at NWR Virtual Healthcare Conference 22 pages 5.2MB
Investor Presentation
2025-03-19 English
Neurotech to present at NWR Virtual Healthcare Conference 1
Investor Presentation
2025-03-17 English
Positive Opinion on OMPD for NTI164 in Europe 2 pages 128.7KB
Capital/Financing Update
2025-02-26 English
Appendix 4D and Half Year Accounts 27 pages 1.1MB
Interim / Quarterly Report
2025-02-26 English
Notification regarding unquoted securities - NTI 9 pages 26.2KB
Share Issue/Capital Change
2025-02-23 English
Change of Director's Interest Notice 2 pages 162.0KB
Director's Dealing
2025-02-23 English
NTI Signs Development Agreement for Cannabinoid Therapies 2 pages 135.3KB
Capital/Financing Update
2025-02-12 English
Initial Director's Interest Notice 2 pages 141.9KB
Director's Dealing
2025-02-03 English
Neurotech Receives $2.44 Million R&D Tax Incentive Refund 1
Regulatory Filings
2025-01-30 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 380.8KB
Interim / Quarterly Report
2025-01-28 English